Clinic Roundup

• Prima BioMed Ltd., of Sydney, Australia, said it started recruiting patients in its CANVAS (CANcer VAccine Study) Phase II/III trial in Europe to test CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer in patients who achieve remission after optimal debulking surgery and standard first-line chemotherapy.